Asthma

Kaleo set to relaunch withdrawn Epipen rival Auvi-Q next year

update - Kaleo wants all patients to have access to Auvi-Q, regardless of insurance coverage

Kaleo set to relaunch withdrawn Epipen rival Auvi-Q next year

By Gareth Macdonald

Kaleo has said it will relaunch Auvi-Q (epinephrine injection) a year after a recall by licensee Sanofi removed the Epipen rival from the market.

Actavis welcomes AZ in boosting its LAMA/LABA

Actavis welcomes AZ in boosting its LAMA/LABA

By Dan Stanton

Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist (LAMA/LABA) fixed dose combination respiratory drug following the latter’s acquisition of Almirall.

Catalent invests $20m

Catalent inhales $20m investment

Catalent will invest $20m to upgrade its US pressurized Metered Dose Inhaler (pMDI) capabilities as part of a wider expansion of its inhaler business.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers